Laurence Buisseret

Dr. Laurence Buisseret

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2020 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
BABertrand Allard
Bertrand Allard
DADavid Allard
David Allard
LBLaurence Buisseret
Laurence Buisseret
John StaggJohn Stagg
John Stagg

18 March 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TGTina Gruosso
Tina Gruosso
MGMathieu Gigoux
Mathieu Gigoux
VMVenkata Satya Kumar Manem
Venkata Satya Kumar Manem
NBNicholas Bertos
Nicholas Bertos
DZDongmei Zuo
Dongmei Zuo
MPMorag Park
Morag Park
Understanding the tumor immune microenvironment (TIME) promises to be key for optimal cancer therapy, especially in triple-negative breast cancer (TNBC). Integrating spatial resolution of immune cells with laser capture microdissection gene expression profiles, we defined distinct TIME stratification in TNBC with implications for current therapies, including immune checkpoint blockade. TNBCs with an immunoreactive microenvironment exhibited tumoral infiltration of granzyme B+ CD8+ T cells, a type I interferon signature, elevated expression of multiple immune inhibitory molecules, including IDO, PD-L1, and good outcome. An “immune-cold” microenvironment with absence of tumoral CD8+ T cells was defined by elevated expression of the immunosuppressive marker B7-H4, signatures of fibrotic stroma and poor outcome. A distinct poor outcome immunomodulatory microenvironment, hitherto poorly characterized, exhibited stromal restriction of CD8+ T cells, stromal expression of PD-L1 and enrichment for signatures of cholesterol biosynthesis. Metasignatures defining these TIME subtypes stratified TNBC, predicting outcome and identifying potential therapeutic targets for TNBC.

13 February 2023 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
VDVéronique Debien
Véronique Debien
ACAlex De Caluwé
Alex De Caluwé
XWXiaoxiao Wang
Xiaoxiao Wang
MPMartine Piccart-Gebhart
Martine Piccart-Gebhart
VTVincent K. Tuohy
Vincent K. Tuohy
LBLaurence Buisseret
Laurence Buisseret
Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting phase 3 clinical trials. These encouraging results lead to the first approvals of immune checkpoint inhibitors in triple-negative breast cancer and thus offer new therapeutic possibilities in aggressive tumors and hard-to-treat populations. Furthermore, several ongoing trials are investigating combining immunotherapies involving immune checkpoint inhibitors with conventional therapies and as well as with other immunotherapeutic strategies such as cancer vaccines, CAR-T cells, bispecific antibodies, and oncolytic viruses in all breast cancer subtypes. This review provides an overview of immunotherapies currently under clinical development and updated key results from clinical trials. Finally, we discuss the challenges to the successful implementation of immune treatment in managing breast cancer and their implications for the design of future clinical trials.

2 June 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
CGChunyan Gu-Trantien
Chunyan Gu-Trantien
EMEdoardo Migliori
Edoardo Migliori
LBLaurence Buisseret
Laurence Buisseret
AWAlexandre de Wind
Alexandre de Wind
SBSylvain Brohée
Sylvain Brohée
KWKaren Willard-Gallo
Karen Willard-Gallo
T follicular helper cells (T FH cells) are important regulators of antigen-specific B cell responses. The B cell chemoattractant CXCL13 has recently been linked with T FH cell infiltration and improved survival in human cancer. Although human T FH cells can produce CXCL13, their immune functions are currently unknown. This study presents data from human breast cancer, advocating a role for tumor-infiltrating CXCL13-producing (CXCR5 – ) T FH cells, here named T FH X13 cells, in promoting local memory B cell differentiation. T FH X13 cells potentially trigger tertiary lymphoid structure formation and thereby generate germinal center B cell responses at the tumor site. Follicular DCs are not potent CXCL13 producers in breast tumor tissues. We used the T FH cell markers PD-1 and ICOS to identify distinct effector and regulatory CD4 + T cell subpopulations in breast tumors. T FH X13 cells are an important component of the PD-1 hi ICOS int effector subpopulation and coexpanded with PD-1 int ICOS hi FOXP3 hi Tregs. IL2 deprivation induces CXCL13 expression in vitro with a synergistic effect from TGFβ1, providing insight into T FH X13 cell differentiation in response to Treg accumulation, similar to conventional T FH cell responses. Our data suggest that human T FH X13 cell differentiation may be a key factor in converting Treg-mediated immune suppression to de novo activation of adaptive antitumor humoral responses in the chronic inflammatory breast cancer microenvironment.

19 September 2019 in JCI Insight
Verified
Journal Article
Closed access
SGSoizic Garaud
Soizic Garaud
LBLaurence Buisseret
Laurence Buisseret
CSCinzia Solinas
Cinzia Solinas
CGChunyan Gu-Trantien
Chunyan Gu-Trantien
AWAlexandre de Wind
Alexandre de Wind
KWKaren Willard-Gallo
Karen Willard-Gallo
Tumor-infiltrating B cells (TIL-B) in breast cancer (BC) have previously been associated with improved clinical outcomes; however, their roles in tumor immunity are not currently well known. This study confirms and extends the correlation between higher TIL-B densities and positive outcomes through an analysis of HER2 + and triple-negative BC patients from the BIG 02-98 clinical trial (10-year median follow-up). Fresh tissue analyses identify an increase in TIL-B density in untreated primary BC compared with normal breast tissues, which is associated with global, CD4 + , and CD8 + tumor infiltrating lymphocytes (TIL); higher tumor grades; higher proliferation; and hormone receptor negativity. All B cell differentiation stages are detectable, but significant increases in memory TIL-B are consistently present. BC with higher infiltrates are specifically characterized by germinal center TIL-B, which in turn are correlated with T follicular helper (T FH ) TIL and antibody-secreting TIL-B principally located in tertiary lymphoid structures. Some TIL-B also interact directly with tumor cells. Functional analyses reveal that TIL-B are responsive to B cell receptor (BCR) stimulation ex vivo, express activation markers, and produce cytokines and Igs despite reduced expression of the antigen-presenting molecules HLA-DR and CD40. Overall, these data support the concept that ongoing humoral immune responses are generated by TIL-B and help to promote effective antitumor immunity at the tumor site.

18 February 2016 in OncoImmunology
Verified
Journal Article
Open access
LBLaurence Buisseret
Laurence Buisseret
SGSoizic Garaud
Soizic Garaud
AWAlexandre de Wind
Alexandre de Wind
GEGert Van Den Eynden
Gert Van Den Eynden
ABAnais Boisson
Anais Boisson
KWKaren Willard-Gallo
Karen Willard-Gallo
The clinical relevance of tumor-infiltrating lymphocytes (TIL) in breast cancer (BC) has been clearly established by their demonstrated correlation with long-term positive outcomes. Nevertheless, the relationship between protective immunity, observed in some patients, and critical features of the infiltrate remains unresolved. This study examined TIL density, composition and organization together with PD-1 and PD-L1 expression in freshly collected and paraffin-embedded tissues from 125 patients with invasive primary BC. Tumor and normal breast tissues were analyzed using both flow cytometry and immunohistochemistry. TIL density distribution is a continuum with 25% of tumors identified as TIL-negative at a TIL density equivalent to normal breast tissues. TIL-positive tumors (75%) were equally divided into TIL-intermediate and TIL-high. Tumors had higher mean frequencies of CD4+ T cells and CD19+ B cells and a lower mean frequency of CD8+ T cells compare with normal tissues, increasing the CD4+/CD8+ T-cell ratio. Tertiary lymphoid structures (TLS), principally located in the peri-tumoral stroma, were detected in 60% of tumors and correlated with higher TIL infiltration. PD-1 and PD-L1 expression were also associated with higher TIL densities and TLS. TIL density, TLS and PD-L1 expression were correlated with more aggressive tumor characteristics, including higher proliferation and hormone receptor negativity. Our findings reveal an important relationship between PD-1/PD-L1 expression, increased CD4+ T and B-cell infiltration, TIL density and TLS, suggesting that evaluating not only the extent but also the nature and location of the immune infiltrate should be considered when evaluating antitumor immunity and the potential for benefit from immunotherapies.